Aripiprazole Tablet
Product Images NDC 43598-970

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 43598-970). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Dr.reddy�s Laboratories Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure-1.jpg (Aripiprazole Figure1)

A scatter plot chart titled 'Effect of Other Drugs on Aripiprazole' showing fold change and 90% confidence intervals for Aripiprazole pharmacokinetic parameters AUC and Cmax. The chart compares changes relative to a reference (without interacting drug) for various inhibitors, inducers, and other drugs including ketoconazole, quinidine, carbamazepine, famotidine, valproate, lithium, and lorazepam.*

FDA Label Image

Figure-2.jpg (Aripiprazole Figure2)

A pharmacokinetic chart showing the effect of various drugs on Aripiprazole metabolism. It plots Dehydro-Aripiprazole fold change with 90% confidence intervals for drugs including CYP3A4 inhibitor ketoconazole, CYP2D6 inhibitor quinidine, CYP3A4 inducer carbamazepine, gastric acid blocker famotidine, and others like valproate, lithium, and lorazepam, relative to a reference without interacting drug.*

FDA Label Image

Figure-3.jpg (Aripiprazole Figure3)

A pharmacokinetic graph showing the effect of Aripiprazole on other drugs. The x-axis represents the fold change relative to reference (without interacting drug). Various drugs and their pharmacokinetic parameters (e.g., AUC, Cmax, INR) are listed on the y-axis, with corresponding fold changes and 90% confidence intervals plotted as points with error bars.*

FDA Label Image

Figure-4.jpg (Aripiprazole Figure4)

A pharmacokinetic chart showing Aripiprazole fold change with 90% confidence intervals in special populations. The chart compares AUC and Cmax values relative to reference across CYP2D6 metabolizer status, gender, age, hepatic impairment levels, and severe renal impairment.*

FDA Label Image

Figure-5.jpg (Aripiprazole Figure5)

A pharmacokinetic chart titled 'Dehydro-Aripiprazole Fold Change and 90% CI' showing fold changes in AUC and Cmax relative to a reference for various factors: CYP2D6 metabolizer status, gender, age groups, hepatic impairment levels, and severe renal impairment. Data points are represented with confidence intervals along a horizontal axis labeled 'Change Relative to Reference.'*

FDA Label Image

Figure-6.jpg (Aripiprazole Figure6)

A Kaplan-Meier curve showing the proportion of subjects with relapse over time for Aripiprazole compared to placebo. The x-axis represents days from randomization, and the y-axis represents the proportion with relapse. The graph includes the number of subjects at risk at various time points for both groups.*

FDA Label Image

Figure 7 (Aripiprazole Figure7)

A Kaplan-Meier curve showing the proportion of subjects with relapse over 182 days from randomization for two groups: Aripiprazole and placebo. The x-axis represents days from randomization, and the y-axis shows the proportion with relapse. The graph includes numbers of subjects at risk for each group at various time points.*

FDA Label Image

Figure 8 (Aripiprazole Figure8)

A line graph depicting the proportion of subjects with relapse over days from randomization, comparing Aripiprazole (solid blue line) and placebo (dashed red line). The x-axis shows days from 0 to 364, and the y-axis shows the proportion with relapse from 0 to 1. The chart includes the number of subjects at risk for each treatment group at various time points beneath the x-axis.*

FDA Label Image

2mg-30 (Aripiprazole Label1)

Label for Aripiprazole Tablets, USP 2 mg, with an NDC of 43598-965-30. The label specifies the tablet strength as 2 mg, package quantity of 30 tablets, and includes pharmacist dispensing instructions. The labeler is Dr. Reddy's Laboratories Inc. Storage instructions and manufacturer details by ScieGen Pharmaceuticals, Inc. and distribution by Dr. Reddy's Laboratories, Inc. are also shown.*

FDA Label Image

5mg-30 (Aripiprazole Label2)

Label for Aripiprazole Tablets, USP, 5 mg oral tablets. The package contains 30 tablets and is labeled for Rx only. It includes storage instructions and manufacturer information, showing Dr. Reddy's Laboratories, Inc. as the distributor and SciGen Pharmaceuticals, Inc. as the manufacturer. The label also advises the pharmacist to dispense the accompanying Medication Guide to each patient.*

FDA Label Image

10mg-30 (Aripiprazole Label3)

Label for Aripiprazole Tablets, USP 10 mg oral tablets by Dr. Reddy's Laboratories Inc. The bottle contains 30 tablets. The label includes dispensing instructions for pharmacists, storage conditions, and manufacturer details. The barcode and a 'NO VARNISH' mark are also visible.*

FDA Label Image

15mg-30 (Aripiprazole Label4)

Label for Aripiprazole Tablets, USP 15 mg oral tablets by Dr. Reddy's Laboratories Inc. The label indicates 30 tablets per container, Rx only, with instructions to dispense the Medication Guide to patients. Storage instructions specify keeping the product in tightly closed containers between 15°C to 30°C (59°F to 86°F). Manufacturer is SciGen Pharmaceuticals, Inc. Bar code and revision date 07/20 are also visible.*

FDA Label Image

20mg-30 (Aripiprazole Label5)

Label for Aripiprazole Tablets, USP 20 mg by Dr. Reddy's Laboratories Inc. The label specifies a bottle of 30 oral tablets, prescription-only, with storage instructions and usual dosage guidance. It includes the NDC number 43598-969-30 and a barcode. The label also states no varnish overprint on the right side.*

FDA Label Image

30mg-30 (Aripiprazole Label6)

Label for Aripiprazole Tablets USP 30 mg, oral tablets produced by Dr. Reddy's Laboratories Inc. The label indicates a package size of 30 tablets and includes storage instructions, dosage guidance, and barcode. The label features the brand name prominently with an emphasis on 30 mg strength.*

FDA Label Image

Structural Formula (Aripiprazole Structure)

Chemical structure diagram of aripiprazole showing its molecular framework including two chlorine atoms attached to a phenyl ring, a substituted piperazine ring, and a quinolinone moiety connected by an ether linkage.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.